

## Research Article

# Prevalence of ESBL-Producing *Enterobacter* Species Resistant to Carbapenems in Iran: A Systematic Review and Meta-Analysis

Farzad Khademi,<sup>1</sup> Hamid Vaez,<sup>2</sup> Zohreh Neyestani,<sup>1</sup> and Amirhossein Sahebkar <sup>3,4,5</sup>

<sup>1</sup>Department of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

<sup>2</sup>Department of Microbiology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran

<sup>3</sup>Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>4</sup>Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>5</sup>Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Amirhossein Sahebkar; [amir\\_saheb2000@yahoo.com](mailto:amir_saheb2000@yahoo.com)

Received 15 September 2021; Revised 28 September 2022; Accepted 11 October 2022; Published 21 October 2022

Academic Editor: Faham Khamesipour

Copyright © 2022 Farzad Khademi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Carbapenems are the last-line therapy for multidrug-resistant (MDR) infections caused by *Enterobacteriales*, including those caused by *Enterobacter* species. However, the recent emergence of carbapenem-resistant (CR) and extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Enterobacteriaceae* pathogens, which are resistant to nearly all antibiotics, has raised concerns among international healthcare organizations. Hence, because there is no comprehensive data in Iran, the current study aimed to evaluate the prevalence of antibiotic resistance among *Enterobacter* species, especially CR and ESBL-producing strains, in Iran. **Methods.** The literature search was performed up to June 21, 2021, in national and international databases using MeSH-extracted keywords, i.e., *Enterobacter*, antibiotic resistance, carbapenem, ESBL, and Iran. Study selection was done based on the predefined inclusion and exclusion criteria, and data analysis was carried out using the Comprehensive Meta-Analysis (CMA) software. **Results.** The pooled prevalence of *Enterobacter* species resistant to various antibiotics is as follows: imipenem 16.6%, meropenem 16.2%, aztreonam 40.9%, ciprofloxacin 35.3%, norfloxacin 31%, levofloxacin 48%, gentamicin 42.1%, amikacin 30.3%, tobramycin 37.2%, tetracycline 50.1%, chloramphenicol 25.7%, trimethoprim/sulfamethoxazole 52%, nalidixic acid 49.1%, nitrofurantoin 43%, ceftriaxone 49.3%, cefixime 52.4%, cefotaxime 52.7%, ceftazidime 47.9%, cefepime 43.6%, and ceftizoxime 45.5%. The prevalence rates of MDR and ESBL-producing *Enterobacter* species in Iran were 63.1% and 32.8%, respectively. **Conclusion.** In accordance with the warning of international organizations, our results revealed a high prevalence of ESBL-producing *Enterobacter* species in Iran, which is probably associated with the high prevalence of *Enterobacter* species resistant to most of the assessed antibiotics, especially MDR strains. However, the resistance rate to carbapenems was relatively low, and these drugs can still be considered as drugs of choice for the treatment of *Enterobacter* infections in Iran. Nevertheless, continuous monitoring of drug resistance along with antibiotic therapy based on the local data and evaluation of the therapeutic efficacy of new antibiotics or combination therapeutic strategies, such as ceftazidime/avibactam, meropenem/vaborbactam, plazomicin, and eravacycline, is recommended.

## 1. Introduction

The genus *Enterobacter* includes three medically important species, i.e., *Enterobacter cloacae* complex, *Enterobacter aerogenes* complex, and *Enterobacter sakazakii* [1, 2]. These enteric Gram-negative rods belong to the *Enterobacteriaceae* family and rarely cause infection in immunocompetent

patients, but they are commonly associated with nosocomial infections, especially by the *Enterobacter cloacae* complex, in neonates and immunocompromised patients [1–6]. The most common nosocomial infections associated with these lactose-fermenting *Enterobacter* species include pneumonia, urinary tract infection, septicemia, and wound infection, as well as device-associated infections [1, 2]. Like many

bacterial infections, in which an increasing trend of antibiotic resistance has led to the emergence of public health problems and imposed economic costs on healthcare, such as an increasing trend of antibiotic resistance has also been reported for *Enterobacter* species [3, 6]. Among different mechanisms of resistance to various antibiotics in these Gram-negative rods, the intrinsic or acquired production of antibiotic-inactivating enzymes such as  $\beta$ -lactamases is very important [1]. *Enterobacter* species producing AmpC chromosomal cephalosporins are intrinsically resistant to ampicillin as well as first- and second-generation cephalosporins [2]. Plasmid-encoded extended-spectrum  $\beta$ -lactamase (ESBL) genes are involved in *Enterobacter* species' resistance to most  $\beta$ -lactam antibiotics, including second- and third-generation cephalosporins and aztreonam [6]. On the other hand, acquired resistance to quinolones, aminoglycosides, and carbapenems has been identified in hospital-acquired strains, which is highly important because these antibiotics are the last line of treatment [2, 4].

Recently, based on the World Health Organization (WHO) report, CR and ESBL-producing *Enterobacteriaceae* have been identified as one of the greatest threats to human health [5]. Although *Escherichia* and *Klebsiella* species are two main threats among CR and ESBL-producing *Enterobacteriaceae* [3], in the United States, CR *Enterobacter* species are considered the second most common CR *Enterobacteriaceae* [6].

However, there is no comprehensive data on antibiotic resistance patterns of *Enterobacter* species, especially CR strains, and ESBL-mediated resistance mechanisms in Iran. Therefore, the current systematic review and meta-analysis were designed to determine the prevalence of antibiotic resistance patterns of *Enterobacter* species, especially carbapenem-resistant strains, along with the frequency of ESBL-producing strains in Iran.

## 2. Methods

**2.1. Literature Search and Study Selection.** International databases including PubMed, Scopus, and Google Scholar, along with national databases including Scientific Information Database (<https://www.sid.ir/>) and Magiran (<https://www.magiran.com/>), were searched independently by two investigators to find studies conducted on the prevalence of antibiotic resistance and ESBL-producing *Enterobacter* species in Iran. The search was performed from 1996 to June 21, 2021. The most common Medical Subject Headings (MeSH)-extracted keywords used for the literature search were as follows: *Enterobacter*, antibiotic resistance, carbapenem, ESBL, and Iran. We defined the inclusion and exclusion criteria for the studies retrieved in the search and selected studies that met our criteria after a review of the titles, abstracts, and full text of the articles. The following studies were removed from the meta-analysis: studies reporting antibiotic resistance and ESBL-positive isolates published in languages other than English or Persian, studies conducted in other countries, studies reporting other bacteria in the *Enterobacteriaceae* family, studies with a small sample size (less than 10 bacterial isolates), studies with

insufficient data, and nonoriginal articles, abstracts, and duplicates. Reference lists of the included articles were checked in order to find any possible missed studies. The current systematic review and meta-analysis were designed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines [7].

**2.2. Data Extraction.** Two different investigators extracted the data, and a third investigator tabulated the required information in Table 1 after resolving possible disagreements in the results of the search and reaching a consensus. Required data were as follows: first author's surname, study location, study enrollment date, the number of isolates, antibiotic susceptibility testing methods, the prevalence of *Enterobacter* species resistance to different drugs, the prevalence of multidrug-resistant (MDR) *Enterobacter* species, and the frequency of ESBL-positive isolates. It is noteworthy that *Enterobacter* species have intrinsic resistance to  $\beta$ -lactam antibiotics including ampicillin, amoxicillin-clavulanate, ampicillin-sulbactam, cephalosporins I (cefazolin and cephalothin), cephamycins (cefoxitin and cefotetan), and cephalosporin II (cefuroxime). According to the Clinical and Laboratory Standards Institute (CLSI) guideline, susceptibility testing is unnecessary for the above-mentioned antibiotics [8]. For this reason, these antibiotics are not included in Table 1.

**2.3. Data Analysis.** In the current study, Cochrane's  $Q$  test (chi-squared,  $\chi^2$ ) and Higgins  $I^2$  statistics were used to assess heterogeneity across the included studies. For this purpose, if the  $p$  value was less than 0.1 for the  $\chi^2$  test and the  $I^2$  value was higher than 25%, the presence of heterogeneity was considered and a random-effects model was applied for the meta-analysis. Extracted data on the prevalence of *Enterobacter* species' antibiotic resistance and ESBL-producing species in Iran were expressed as a percentage and 95% confidence intervals (95% CIs). Additionally, a subgroup analysis was performed based on the location of the study. A funnel plot-based method was used for reporting the presence or absence of publication bias in the meta-analyses, and it was considered a potential sign of publication bias if the graph showed an asymmetric shape. The Comprehensive Meta-Analysis (CMA) software (Biostat, Englewood, NJ) was used for the meta-analysis.

## 3. Results

Among 19,669 eligible studies published from 1996 until June 21, 2021, 49 articles (20 in Persian and 29 in English) met the inclusion criteria and were included in the meta-analysis (Figure 1). As shown in Table 1, data were obtained from 19 cities (Ahvaz ( $n=5$ ), Arak ( $n=1$ ), Babol ( $n=2$ ), Bojnurd ( $n=1$ ), Fasa ( $n=1$ ), Hamadan ( $n=1$ ), Ilam ( $n=1$ ), Isfahan ( $n=2$ ), Jahrom ( $n=1$ ), Kashan ( $n=1$ ), Kerman ( $n=1$ ), Kermanshah ( $n=2$ ), Rasht ( $n=2$ ), Sanandaj ( $n=4$ ), Semnan ( $n=1$ ), Shiraz ( $n=4$ ), Tabriz ( $n=2$ ), Tehran ( $n=13$ ), and Zahedan ( $n=1$ )) in Iran. All studies used the disk diffusion method for antimicrobial susceptibility

TABLE 1: Required data were extracted from included articles in the meta-analysis.

Author (Ref)	City	Year	Isolate (n)	AST	Resistance rate (n)																ESBL-positive (n)				
					IPM	MEM	ATM	CIP	NOR	LVX	GEN	AMK	TOB	TET	CHL	SXT	NAL	NIT	CRO	CFM		CTX	CAZ	CEP	ZOX
Amin et al. [9]	Ahvaz	2015-2016	152	Disk diffusion	80	53	ND	84	70	63	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Afrugh et al. [10]	Ahvaz	2013-2014	17	Disk diffusion	15	15	ND	15	ND	ND	14	16	ND	17	ND	12	16	13	16	ND	17	15	14	16	ND
Mousavian et al. [11]	Ahvaz	2012	65	Disk diffusion	0	ND	ND	6	ND	ND	5	3	ND	ND	ND	ND	ND	ND	10	ND	11	9	ND	11	ND
Khosravi et al. [12]	Ahvaz	2009-2012	156	Disk diffusion	98	ND	ND	91	ND	ND	102	60	ND	64	ND	108	94	75	121	110	ND	ND	ND	ND	ND
Khosravi et al. [13]	Ahvaz	2009-2010	209	Disk diffusion	124	ND	ND	88	ND	ND	143	117	ND	124	ND	146	119	117	143	148	ND	ND	ND	ND	ND
Didgar [14]	Arak	2010-2012	47	Disk diffusion	6	ND	ND	19	ND	ND	19	18	ND	ND	ND	20	ND	ND	29	ND	ND	40	25	19	ND
Ghasemi et al. [15]	Babol	2020	30	Disk diffusion	6	ND	ND	6	ND	ND	4	6	ND	ND	ND	ND	ND	9	ND	ND	10	ND	28	ND	28
Bayani et al. [16]	Babol	2011-2012	30	Disk diffusion	2	ND	ND	2	ND	ND	2	2	ND	ND	ND	ND	ND	ND	ND	ND	ND	5	4	ND	0
Ghafouri et al. [17]	Bojnurd	2013	12	Disk diffusion	3	5	ND	8	ND	ND	8	2	ND	3	0	6	ND	1	6	0	0	1	ND	ND	ND
Peymani et al. [18]	Different cities	2014	49	Disk diffusion	2	2	27	16	ND	ND	20	11	ND	ND	ND	25	ND	ND	28	ND	34	27	ND	ND	26
Peymani et al. [19]	Different cities	2011-2012	137	Disk diffusion	2	1	67	22	16	ND	59	ND	ND	ND	ND	83	ND	ND	78	ND	80	71	ND	ND	83
Poorabbas et al. [20]	Different cities	2008-2009	38	Disk diffusion	38	ND	ND	33	ND	35	24	26	0	ND	ND	22	ND	22	18	13	19	20	24	ND	ND
Molazade et al. [21]	Fasa	2012-2013	28	Disk diffusion	ND	ND	ND	11	ND	ND	8	0	ND	11	ND	14	11	11	11	11	0	ND	ND	ND	ND
Esmaeili et al. [22]	Hamadan	2011	15	Disk diffusion	ND	ND	ND	13	ND	ND	13	ND	13	ND	10	6	4	11	ND	ND	ND	ND	ND	ND	ND
Yasemi et al. [23]	Ilam	2007-2009	20	Disk diffusion	ND	ND	ND	ND	ND	ND	3	ND	ND	ND	ND	9	ND	6	ND	ND	ND	ND	ND	ND	ND
Fatemi et al. [24]	Isfahan	2014-2015	135	Disk diffusion	13	16	93	58	ND	ND	54	46	53	96	26	23	ND	ND	ND	ND	89	87	90	ND	98
Shokri et al. [25]	Isfahan	2012-2013	35	Disk diffusion	3	3	ND	21	ND	ND	22	10	ND	ND	ND	ND	6	ND	ND	24	22	12	ND	35	ND
Kargar et al. [26]	Jahrom	2011-2012	25	Disk diffusion	ND	ND	ND	ND	ND	ND	17	7	11	24	ND	20	24	ND	ND	ND	10	10	ND	ND	1
Shajari et al. [27]	Kashan	2005-2006	35	Disk diffusion	10	ND	ND	13	ND	ND	14	12	11	ND	ND	21	28	ND	18	22	22	ND	ND	ND	ND
Sepehri et al. [28]	Kerman	1996, 2000	72	Disk diffusion	ND	ND	ND	ND	ND	ND	43	ND	ND	ND	ND	46	12	28	ND	ND	ND	ND	ND	ND	ND
Mortazavi et al. [29]	Kermanshah	2016-2017	72	Disk diffusion	7	ND	29	35	30	ND	36	35	ND	ND	ND	49	31	16	ND	40	37	38	ND	ND	54
Amiri et al. [30]	Kermanshah	2015	18	Disk diffusion	ND	ND	ND	7	ND	ND	8	9	ND	ND	ND	13	7	5	6	6	ND	10	ND	ND	ND
Karambin and Zarkesh [31]	Rasht	2008-2010	50	Disk diffusion	ND	ND	ND	0	ND	ND	15	41	ND	ND	ND	40	ND	ND	ND	ND	43	ND	ND	ND	ND
Yaghubi et al. [32]	Rasht	2013-2015	147	Disk diffusion	79	61	ND	80	ND	ND	81	66	78	0	ND	108	105	102	102	119	109	92	ND	80	ND
Rouhi et al. [33]	Sanandaj	2013-2014	10	Disk diffusion	2	ND	ND	2	0	ND	0	5	ND	2	ND	ND	0	0	3	ND	5	4	ND	5	ND

TABLE 1: Continued.

Author (Ref)	City	Year	Isolate (n)	AST	Resistance rate (n)																ESBL-positive (n)						
					IPM	MEM	ATM	CIP	NOR	LVX	GEN	AMK	TOB	TET	CHL	SXT	NAL	NIT	CRO	CFM		CTX	CAZ	CEP	ZOX	MDR	
Nikkhoo et al. [34]	Sanandaj	2009-2010	11	Disk diffusion	ND	ND	ND	3	ND	ND	7	6	ND	ND	7	ND	2	ND	ND	6	5	5	ND	ND	ND	ND	
Ramazanzadeh et al. [35]	Sanandaj	2007-2008	28	Disk diffusion	ND	ND	ND	14	22	ND	3	6	ND	ND	ND	13	23	ND	9	ND	9	ND	7	7	ND	5	ND
Afkhamzadeh et al. [36]	Sanandaj	2007-2008	15	Disk diffusion	ND	ND	ND	10	ND	ND	11	7	ND	ND	10	ND	10	ND	13	ND	13	4	ND	ND	ND	ND	ND
Jazayeri [37]	Semnan	1999	11	Disk diffusion	ND	ND	ND	5	ND	ND	5	ND	ND	ND	ND	10	10	ND	8	ND	ND	ND	ND	ND	ND	ND	ND
Khashei et al. [38]	Shiraz	2016-2017	96	Disk diffusion	21	ND	ND	31	ND	ND	39	22	ND	ND	ND	45	ND	68	ND	ND	ND	70	ND	ND	93	35	
Malekzadegan et al. [39]	Shiraz	2015-2016	61	Disk diffusion	26	ND	ND	30	ND	ND	46	61	ND	ND	ND	21	3	4	ND	ND	ND	55	ND	ND	56	ND	
Nematollahi et al. [40]	Shiraz	2005-2014	90	Disk diffusion	4	1	44	14	ND	ND	33	27	ND	ND	30	ND	ND	52	62	55	47	34	ND	10	14		
Mardaneh et al. [41]	Shiraz	2013	33	Disk diffusion	2	7	14	5	ND	ND	11	7	14	24	8	9	ND	14	19	15	13	13	ND	ND	13		
Rezaee and Abdinia [42]	Tabriz	2010-2014	40	Disk diffusion	ND	ND	ND	0	ND	ND	20	0	ND	ND	ND	40	40	20	ND	40	ND	ND	10	40	ND	ND	
Hamishehkar et al. [43]	Tabriz	2010-2012	282	Disk diffusion	61	ND	ND	89	ND	ND	84	61	ND	ND	78	109	ND	25	79	ND	41	55	ND	49	ND	ND	
Azimi et al. [44]	Tehran	2013-2018	45	Disk diffusion	8	23	11	9	ND	7	26	15	36	45	ND	20	9	45	30	ND	38	31	32	39	12	ND	
Akhaivazadegan et al. [45]	Tehran	2016-2017	18	Disk diffusion	0	ND	ND	7	ND	7	ND	0	ND	ND	ND	8	6	2	5	7	ND	4	2	ND	ND	ND	
Sohrabi fard et al. [46]	Tehran	2014-2015	12	Disk diffusion	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	4	ND	ND	5	ND	ND	ND	ND	ND	ND	ND	ND	
Ghanavati et al. [47]	Tehran	2013-2014	57	Disk diffusion	8	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	28	21	ND	10	30	
Salimian rizi et al. [48]	Tehran	2012-2013	45	Disk diffusion	0	ND	14	6	ND	ND	10	6	10	26	8	28	ND	ND	ND	ND	13	15	7	ND	45	ND	
Mahmoudi et al. [49]	Tehran	2011-2016	100	Disk diffusion	4	ND	ND	ND	ND	ND	27	30	ND	ND	ND	20	ND	ND	ND	ND	69	ND	36	ND	46	ND	
Rajabi et al. [50]	Tehran	2011-2012	17	Disk diffusion	ND	ND	ND	2	ND	ND	ND	ND	ND	2	ND	2	ND	9	ND	ND	ND	ND	ND	ND	ND	ND	
Afsharpaiman et al. [51]	Tehran	2011	33	Disk diffusion	5	0	ND	ND	ND	ND	17	14	ND	ND	16	18	11	30	14	14	30	22	ND	9	ND	ND	
Rahbar et al. [52]	Tehran	2010-2011	101	Disk diffusion	2	ND	14	ND	ND	ND	15	3	19	19	19	20	ND	ND	ND	ND	20	23	5	ND	ND	33	
Ranjbar et al. [53]	Tehran	2006-2007	83	Disk diffusion	ND	ND	ND	32	ND	ND	41	49	44	ND	22	47	47	60	45	50	ND	54	ND	53	ND	ND	
Taheri et al. [54]	Tehran	2004-2012	14	Disk diffusion	ND	ND	ND	ND	0	ND	9	4	ND	ND	ND	6	1	5	2	ND	ND	0	ND	2	ND	ND	
Haghi et al. [55]	Tehran	2003-2004	39	Disk diffusion	ND	ND	ND	ND	ND	ND	13	5	11	ND	ND	17	23	13	16	ND	16	ND	12	ND	ND	ND	
Navidinia et al. [56]	Tehran	NA	69	Disk diffusion	1	1	ND	12	ND	ND	5	2	4	ND	ND	ND	ND	39	ND	ND	ND	43	67	4	ND		
Sadeghi bojd et al. [57]	Zahedan	2013-2015	32	Disk diffusion	ND	ND	ND	3	ND	ND	2	3	ND	ND	ND	14	9	2	6	6	6	ND	ND	ND	ND	ND	

IPM-imipenem; MEM-meropenem; ATM-aztreonam; CIP-ciprofloxacin; LVX-levofloxacin; GEN-gentamicin; AMK-amikacin; TOB-tobramycin; TET-tetracycline; CHL-chloramphenicol; SXT-trimethoprim/sulfamethoxazole; NAL-nalidixic acid; NIT-nitrofurantoin; CRO-ceftriaxone; CFM-cefexime; CTX-ceftazidime; CAZ-ceftazidime; CEP-cefepime; ZOX-ceftiozime; MDR-multidrug-resistant; ESBL-extended-spectrum  $\beta$ -lactamase; AST-antimicrobial susceptibility testing; ND-not determined.




FIGURE 1: A schematic view of the study selection process.

testing. The pooled prevalence of *Enterobacter* species' resistance to various antibiotics was as follows: imipenem 16.6% (95% CI: 11–24.1;  $I^2 = 93.1\%$ ;  $Q = 439.9$ ;  $p \leq 0.001$ ) (Figure 2), meropenem 16.2% (95% CI: 8.9–27.9;  $I^2 = 89.8\%$ ;  $Q = 117.8$ ;  $p \leq 0.001$ ), aztreonam 40.9% (95% CI: 29.6–53.2;  $I^2 = 89.3\%$ ;  $Q = 75$ ;  $p \leq 0.001$ ), ciprofloxacin 35.3% (95% CI: 29.5–41.6;  $I^2 = 86.1\%$ ;  $Q = 273.6$ ;  $p \leq 0.001$ ), norfloxacin 31% (95% CI: 14.3–54.7;  $I^2 = 91.6\%$ ;  $Q = 59.9$ ;  $p \leq 0.001$ ), levofloxacin 48% (95% CI: 21.3–75.9;  $I^2 = 90.7\%$ ;  $Q = 32.4$ ;  $p \leq 0.001$ ), gentamicin 42.1% (95% CI: 36.2–48.3;  $I^2 = 87.2\%$ ;  $Q = 328.5$ ;  $p \leq 0.001$ ), amikacin 30.3% (95% CI: 24.5–36.8;  $I^2 = 86.9\%$ ;  $Q = 298.8$ ;  $p \leq 0.001$ ), tobramycin 37.2% (95% CI: 26.3–49.5;  $I^2 = 88.3\%$ ;  $Q = 103.1$ ;  $p \leq 0.001$ ), tetracycline 50.1% (95% CI: 37.3–62.9;  $I^2 = 88\%$ ;  $Q = 134$ ;  $p \leq 0.001$ ), chloramphenicol 25.7% (95% CI: 20.5–31.6;  $I^2 = 61.1\%$ ;  $Q = 20.5$ ;  $p \leq 0.001$ ), trimethoprim/sulfamethoxazole 52% (95% CI: 45.4–58.6;  $I^2 = 87.5\%$ ;  $Q = 304.9$ ;  $p \leq 0.001$ ), nalidixic acid 49.1% (95% CI: 38.8–59.4;  $I^2 = 87.6\%$ ;  $Q = 177.4$ ;  $p \leq 0.001$ ), nitrofurantoin 43% (95% CI: 32.4–54.2;  $I^2 = 91.7\%$ ;  $Q = 328.8$ ;  $p \leq 0.001$ ), ceftriaxone 49.3% (95% CI: 41.8–56.9;  $I^2 = 87.1\%$ ;  $Q = 226.1$ ;  $p \leq 0.001$ ), cefixime 52.4% (95% CI: 43.7–61;  $I^2 = 83.4\%$ ;  $Q = 102.5$ ;  $p \leq 0.001$ ), cefotaxime 52.7% (95% CI: 42.4–62.7;  $I^2 = 91.9\%$ ;  $Q = 359.3$ ;  $p \leq 0.001$ ), ceftazidime 47.9% (95% CI: 39.8–56.2;  $I^2 = 89.7\%$ ;  $Q = 302$ ;  $p \leq 0.001$ ), cefepime 43.6% (95% CI: 31.3–56.8;  $I^2 = 90.1\%$ ;  $Q = 142.2$ ;  $p \leq 0.001$ ) and ceftizoxime 45.5% (95% CI: 30.6–61.3;  $I^2 = 92.7\%$ ;  $Q = 178.4$ ;  $p \leq 0.001$ ).

In addition, Table 2 shows the antibiotic resistance profiles of *Enterobacter* species in different cities of Iran. The rate of MDR *Enterobacter* species in Iran was 63.1% (95% CI: 45.2–78;  $I^2 = 93.9\%$ ;  $Q = 249.1$ ;  $p \leq 0.001$ ).

In addition, the prevalence of ESBL-producing *Enterobacter* species was 32.8% (95% CI: 23.3–44;  $I^2 = 79.4\%$ ;  $Q = 29.1$ ;  $p \leq 0.001$ ) in Iran.

It should be noted that a random-effects model was applied for the meta-analysis due to the existence of high heterogeneity across the included studies in this study.


#### 4. Discussion

The emergence of MDR- and ESBL-producing *Enterobacteriaceae*, including *Enterobacter* species, has increased the necessity to deal with these organisms [5, 6]. The Centers for Disease Control and Prevention (CDC) estimated 197,400 cases of ESBL-producing *Enterobacteriaceae* along with 9,100 deaths among hospitalized patients in the United States in 2017 [58]. The antibiotic of choice to treat infections caused by MDR and ESBL-producing *Enterobacteriaceae* is carbapenem [3, 58, 59]. However, the widespread use of carbapenem antibiotics has led to the emergence of CR bacteria [3, 59]. According to the CDC report for 2019, increased prevalence of CR *Enterobacteriaceae*, especially CR *Enterobacter cloacae* complex, has become a public health issue in the United States [58].


In Iran, the prevalence of MDR (63.1%) and ESBL-producing *Enterobacter* species (32.8%) was high. This is an alarming rate despite the relatively low frequency of imipenem- and meropenem-resistant *Enterobacter* species in Iran. The results suggest that carbapenems are still the drugs of choice for the treatment of infections caused by MDR and ESBL-producing *Enterobacter* species in Iran. The distribution of ESBL-producing *Enterobacter* species in other countries was as follows: Pakistan 14.9%, Nigeria 37.5%, and Ethiopia 50% [60, 61].

The CDC has reported that CR *Enterobacteriaceae*-associated infections frequently occur in patients using medical devices, including catheters (intravenous and urinary) and ventilators, and some of these microorganisms are resistant to all available antibiotics, hence their infections are

Meta Analysis



(a)



(b)

FIGURE 2: Forest plots (a) and funnel plots (b) illustrate the prevalence of imipenem-resistant *Enterobacter* species in Iran.

TABLE 2: Antibiotic resistance profile of *Enterobacter* isolates from cities in Iran.

City	Percentage resistance (%)																			
	IPM	MEM	ATM	CIP	NOR	LVX	GEN	AMK	TOB	TET	CHL	SXT	NAL	NIT	CRO	CFM	CTX	CAZ	CEP	ZOX
Ahvaz	58	64.4	NA	46.8	46.1	41.4	53.1	40.9	NA	56.7	NA	69.6	61.2	55.1	63.6	70.7	68.8	50.9	82.4	61.8
Arak	12.8	NA	NA	40.4	NA	NA	40.4	38.3	NA	NA	NA	42.6	NA	NA	61.7	NA	NA	85.1	53.2	40.4
Babol	13.2	NA	NA	13.2	NA	NA	13.3	13.2	NA	NA	NA	NA	NA	30	NA	NA	33.3	16.7	58.8	NA
Bojnurd	25	41.7	NA	66.7	NA	NA	66.7	16.7	NA	25	3.8	50	NA	8.3	50	3.8	3.8	8.3	NA	NA
Fasa	NA	NA	NA	39.3	NA	NA	28.6	1.7	NA	39.3	NA	50	39.3	39.3	39.3	39.3	1.7	NA	NA	NA
Hamadan	NA	NA	NA	86.7	NA	NA	86.7	NA	86.7	NA	NA	66.7	40	26.7	73.3	NA	NA	NA	NA	NA
Ilam	NA	NA	NA	NA	NA	NA	15	NA	NA	NA	NA	45	NA	30	NA	NA	NA	NA	NA	NA
Isfahan	9.4	11.3	68.9	49.9	NA	NA	50.3	33	39.3	71.1	19.3	17	NA	17.1	NA	NA	66.5	64.1	51.4	NA
Jahrom	NA	NA	NA	NA	NA	NA	68	28	44	96	NA	80	96	NA	NA	NA	40	40	NA	NA
Kashan	28.6	NA	NA	37.1	NA	NA	40	34.3	31.4	NA	NA	60	80	NA	NA	51.4	62.9	62.9	NA	NA
Kerman	NA	NA	NA	NA	NA	NA	59.7	NA	NA	NA	NA	63.9	16.7	38.9	NA	NA	NA	NA	NA	NA
Kermanshah	9.7	NA	40.3	46.7	41.7	NA	48.9	48.9	NA	NA	NA	68.9	42.2	23.4	33.3	46.8	51.4	53.3	NA	NA
Rasht	53.7	41.5	NA	11.8	NA	NA	42.8	65.1	53.1	0.3	NA	75	71.4	69.4	69.4	81	79.4	62.6	NA	54.4
Sanandaj	20	NA	NA	43.2	34.2	NA	33.5	40.5	NA	51.6	NA	45.2	36.4	4.5	50.7	45.5	51.2	28.6	NA	30.7
Semnan	NA	NA	NA	45.5	NA	NA	45.5	NA	NA	NA	NA	90.9	90.9	90.9	NA	72.7	NA	NA	NA	NA
Shiraz	15.1	5.9	47.2	26.9	NA	NA	46.8	34.7	42.4	72.7	31.1	37.5	4.9	29.9	51.7	65.1	54.8	66.5	38.2	NA
Tabriz	21.6	NA	NA	9.1	NA	NA	38.3	7.5	NA	NA	27.7	85.3	98.8	70.8	37.4	NA	75.9	19.5	NA	19
Tehran	6.3	6.7	22	22.9	3.3	25	33.1	18.9	31.2	42.8	26.4	39.4	36.3	63.1	45.3	47.6	58.6	41.8	28.8	59.2
Zahedan	NA	NA	NA	9.4	NA	NA	6.3	9.4	NA	NA	NA	43.8	28.1	6.3	18.8	18.8	18.8	NA	NA	NA

NA-not available.

difficult to treat [58]. Currently, the available antimicrobial agents for the treatment of CR *Enterobacteriaceae* are limited [62]. Historically, aminoglycosides, tigecycline, polymyxins, and fosfomycin have been used as therapeutic options for this purpose [62]. However, according to the included articles in this study, there is insufficient data on the prevalence of tigecycline-, polymyxins-, and fosfomycin-resistant *Enterobacter* species in Iran. Hence, the evaluation of *Enterobacter* species resistance rates to these antibiotics is recommended. In the present study, the rate of tetracycline-resistant *Enterobacter* species was high (50.1%).

On the other hand, aminoglycosides, including gentamicin, amikacin, and tobramycin, are also recommended as anti-CR *Enterobacteriaceae* therapies [62]. However, based on the present study, the prevalence of gentamicin-, amikacin-, and tobramycin-resistant *Enterobacter* species was high in Iran. It is recommended that older antibiotics such as trimethoprim/sulfamethoxazole and chloramphenicol may be effective for the treatment of infections caused by CR *Enterobacteriaceae* pathogens [62]. Our results showed that the prevalence of *Enterobacter* species resistant to chloramphenicol was higher than those resistant to trimethoprim/sulfamethoxazole (25.7% vs. 52%). Other treatment options for infections caused by CR *Enterobacteriaceae* include combination strategies (high-dose tigecycline, high-dose carbapenem, and double-carbapenem therapy), new antibiotics (ceftazidime/avibactam, meropenem/vaborbactam, plazomicin, and eravacycline), and new antibiotics in development (imipenem/cilastatin, relebactam, and cefiderocol) [62]. However, information on the therapeutic efficacy of these drugs against CR *Enterobacter* species is not available in Iran (according to the included articles in this study). Based on the current study, the frequency of meropenem and ceftazidime-resistant *Enterobacter* species was 16.2% and 47.9%, respectively. *Enterobacter* species' drug resistance rates to the third-generation cephalosporins and aztreonam were high in Iran. Considering the prevalence of ESBL-producing *Enterobacter* species in this study (32.8%), it seems that these ESBLs are involved in resistance to third-generation cephalosporins and aztreonam in Iran. The CDC estimated the rate of quinolone-resistant *Enterobacter* species as 30% [3]; however, the prevalence of *Enterobacter* species resistant to quinolones was higher in this study.

Such a high antibiotic resistance of *Enterobacter* species, especially MDR, in this study can be attributed to the indiscriminate use of antibiotics and easy, without a prescription, access to antibiotics and self-medication in Iran [63, 64]. On the other hand, since *Enterobacter* species are responsible for nosocomial infections, using appropriate infection control programs and practices of hygiene such as hand decontamination, glove use, sterilization, and disinfection practices can play an important role in preventing the spread of resistant strains in healthcare settings.

One of the limitations of the current study was the inability to compare the obtained results with other countries, particularly adjacent countries, which needs to be addressed in future multicenter and international studies.

## 5. Conclusion

This study is the first systematic review and meta-analysis reporting *Enterobacter* species antibiotic resistance in Iran. The results of this meta-analysis indicated the high prevalence of *Enterobacter* species resistant to the majority of assessed antibiotics in the included studies, i.e., quinolones, aminoglycosides, third- and fourth-generation cephalosporins, aztreonam, tetracycline, chloramphenicol, trimethoprim/sulfamethoxazole, and nitrofurantoin. In addition, the prevalence rates of ESBL-producing *Enterobacter* species (32.8%) and MDR (63.1%) strains were high in Iran. Such an increasing trend of antibiotic resistance in *Enterobacter* species can impose more economic costs on healthcare systems in Iran due to prolonged periods of hospitalization, increased drug consumption, poor patient outcomes, and higher mortality and morbidity. In total, we suggest the management of antibiotic prescription, launching and developing health education and infection control programs, continuous monitoring of drug resistance, and evaluation of the therapeutic efficacy of new antimicrobial agents (herbal medicine and new antimicrobial peptides) or combination therapeutic strategies are required to control *Enterobacter* species-associated infections and antibiotic resistance in Iran. Finally, in comparison with the above-mentioned antibiotics, the prevalence of CR *Enterobacter* species was relatively low in Iran, and it seems that carbapenems can still be considered as drugs of choice for the treatment of MDR and ESBL-producing *Enterobacter* species.

## Data Availability

No data were used to support this study.

## Conflicts of Interest

The authors declare that there are no conflicts of interest.

## References

- [1] É Ruppé, P. L. Woerther, and F. Barbier, "Mechanisms of antimicrobial resistance in gram-negative bacilli," *Annals of Intensive Care*, vol. 5, no. 1, pp. 21–25, 2015.
- [2] K. C. Carroll, J. S. Butel, and S. A. Morse, *Jawetz Melnick & Adelbergs Medical Microbiology*, McGraw Hill Professional, New York, NY, USA, 2016.
- [3] M. S. Morehead and C. Scarbrough, "Emergence of global antibiotic resistance," *Primary Care: Clinics in Office Practice*, vol. 45, no. 3, pp. 467–484, 2018.
- [4] V. T. Anju, B. Siddhardha, and M. Dyavaiah, "Enterobacter infections and antimicrobial drug resistance," in *Model Organisms for Microbial Pathogenesis, Biofilm Formation and Antimicrobial Drug Discovery 2020* Springer, Berlin, Germany, 2020.
- [5] World Health Organization, *WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed*, WHO, Geneva, Switzerland, 2017.
- [6] M. K. Annavajhala, A. Gomez-Simmonds, and A. C. Uhlemann, "Multidrug-resistant *Enterobacter cloacae*



- complex emerging as a global, diversifying threat,” *Frontiers in Microbiology*, vol. 10, p. 44, 2019.
- [7] A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” *PLoS Medicine*, vol. 6, no. 7, Article ID e1000100, 2009.
- [8] Clinical and Laboratory Standards Institute, *Performance Standards for Antimicrobial Susceptibility Testing—Twenty-Eighth Informational Supplement. CLSI Document M100*, Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2021.
- [9] M. Amin, S. Dibachi, and M. Shahin, “Prevalence of class I integrons and plasmid-mediated *qnr*-genes among *Enterobacter* isolates obtained from hospitalized patients in Ahvaz, Iran,” *Informe Medico*, vol. 25, no. 4, pp. 351–357, 2017.
- [10] P. Afrugh, J. Mardaneh, A. Kaidani, A. A. Serajian, P. Abbasi, and M. Yahyavi, “Distribution and antimicrobial susceptibility pattern of gram negative bacteria causing urinary tract infection (UTI) and detection New Delhi metallo-beta-lactamase-1 (NDM-1) producing isolates in ahvaz,” *Iranian South Medical Journal*, vol. 19, no. 1, pp. 15–26, 2016.
- [11] S. M. Mousavian, N. Ahmad Khosravi, and S. Shoja, “Survey of frequency in extended-spectrum beta lactamase producing *Enterobacteriaceae* and determination of the antibiotic resistant pattern in clinical specimens in teaching hospitals of Ahvaz Jundishapur university of medical sciences,” *Jundishapur Scientific Medical Journal (JSMJ)*, vol. 13, no. 2, pp. 1–9, 2014.
- [12] A. D. Khosravi, E. Abasi Montazeri, A. Ghorbani, and N. Parhizgari, “Bacterial urinary tract infection in renal transplant recipients and their antibiotic resistance pattern: a four-year study,” *Iranian Journal of Microbiology*, vol. 6, no. 2, pp. 74–78, 2014.
- [13] A. D. Khosravi, N. Parhizgari, E. Montazeri, A. Mozaffari, and F. Abbasi, “The prevalence of bacteria isolated from endotracheal tubes of patients in Golestan Hospital, Ahvaz, Iran, and determination of their antibiotic susceptibility patterns,” *Jundishapur Journal of Microbiology*, vol. 6, no. 1, pp. 67–71, 2012.
- [14] F. Didgar, H. Sarmadian, and R. Ghasemikhah, “Antimicrobial resistance pattern of gram-negative bacilli isolated of Vali-Asr Hospital wards in Arak,” *Iranian South Medical Journal*, vol. 17, no. 5, pp. 938–947, 2014.
- [15] E. Ghasemi, E. Ferdosi-Shahandashti, M. Rajabnia, P. Sabbagh, A. Maali, and A. Ferdosi-Shahandashti, “Class I integrons among multidrug resistant *Enterobacter* spp. isolates from hospitalized patients in Babol, North of Iran,” *Caspian Journal of Internal Medicine*, vol. 12, no. 1, pp. 65–69, 2021.
- [16] M. Bayani, S. Siadati, R. Rajabnia, and A. A. Taher, “Drug resistance of *Pseudomonas aeruginosa* and *Enterobacter cloacae* isolated from ICU, Babol, northern Iran,” *International Journal of Molecular and Cellular Medicine*, vol. 2, no. 4, pp. 204–209, 2013.
- [17] M. Ghafouri, S. A. Hashemi, A. Azimian, T. Garevani, and S. H. SeyedSharifi, “Evaluation of antibiotic resistance to bacteria isolated from patients with nosocomial infections hospitalized in Imam Reza in Bojnurd City in 2013,” *Journal of Rafsanjan University of Medical Sciences*, vol. 14, no. 7, pp. 599–610, 2015.
- [18] A. Peymani, M. Yeylagh Beigi, M. Mohammadi Ghanbarlou, R. Najafipour, and R. Samimi, “Multidrug resistance in *Pseudomonas aeruginosa* and *Enterobacter cloacae* isolated from intensive care units of Qazvin and Tehran hospitals,” *Journal of Clinical Research in Paramedical Sciences*, vol. 3, no. 1, pp. 16–24, 2014.
- [19] A. Peymani, T. N. Farivar, P. Ghoraiian, and R. Najafipour, “Association between class I integrons and multidrug resistance pattern among *Enterobacter* spp. isolated from Qazvin and Tehran teaching hospitals,” *Journal of Qazvin University of Medical Sciences*, vol. 18, no. 2, pp. 30–38, 2014.
- [20] B. Poorabbas, J. Mardaneh, Z. Rezaei et al., “Nosocomial infections: multicenter surveillance of antimicrobial resistance profile of *Staphylococcus aureus* and gram negative rods isolated from blood and other sterile body fluids in Iran,” *Iranian Journal of Microbiology*, vol. 7, no. 3, pp. 127–135, 2015.
- [21] A. Molazade, M. S. Gholami, A. Shahi et al., “Evaluation of antibiotic resistance pattern of isolated gram-negative bacteria from urine culture of hospitalized patients in different wards of vali-asr hospital in Fasa during the years 2012 and 2013,” *Journal of Fasa University of Medical Science*, vol. 4, no. 3, pp. 275–283, 2014.
- [22] R. Esmaili, H. Hashemi, M. Moghadam Shakib, M. Alikhani, and Z. Sohrabi, “Bacterial etiology of urinary tract infections and determining their antibiotic resistance in adults hospitalized in or referred to the Farschian hospital in Hamadan,” *Journal of Ilam University of Medical Sciences*, vol. 21, pp. 281–287, 2013.
- [23] M. Yasemi, H. Peyman, K. Asadollahi et al., “Frequency of bacteria causing urinary tract infections and their antimicrobial resistance patterns among pediatric patients in Western Iran from 2007–2009,” *Journal of Biological Regulators & Homeostatic Agents*, vol. 28, no. 3, pp. 443–448, 2014.
- [24] S. M. Fatemi, D. Shokri, S. Mohammadi, and H. Koupahi, “Investigation of NDM metallo-beta-lactamase and CMY-2 AmpC  $\beta$ -lactamase production in *Escherichia coli* and *Enterobacter* spp. isolated from human,” *Comparative Clinical Pathology*, vol. 27, no. 4, pp. 1007–1015, 2018.
- [25] D. Shokri, S. Mobasherizadeh, S. M. Fatemi, R. Moayednia, and M. Sadeghi Naeeni, “Hospital based surveillance of carbapenem resistance in multidrug-resistant (MDR) strains of *Enterobacter* and *Escherichia coli* in Isfahan,” *Journal of Microbial World*, vol. 8, no. 22, pp. 64–75, 2015.
- [26] M. Kargar, M. Jahromi, M. Kargar, A. Najafi, and S. Ghorbani-Dalini, “Molecular detection of ESBLs production and antibiotic resistance patterns in gram negative bacilli isolated from urinary tract infections,” *Indian Journal of Pathology & Microbiology*, vol. 57, no. 2, pp. 244–248, 2014.
- [27] G. H. Shajari, A. Khorshidi, and G. H. Moosavi, “Bacterial isolation and antibiotic resistance of nosocomial pneumonia in hospitalized patients-Kashan, Iran,” *Hormozgan Medical Journal*, vol. 13, no. 3, pp. 197–205, 2009.
- [28] G. R. Sepehri, S. Dabiri, and M. R. Vosoogh, “Comparison the sensitivity of microbial agents causing urinary tract infections to commonly used antibiotics in kerman in the years 1996 and 2000,” *Journal of Rafsanjan University of Medical Sciences*, vol. 3, no. 4, pp. 216–224, 2004.
- [29] S. H. Mortazavi, F. Mansouri, M. Azizi et al., “Prevalence of class I and II integrons among MDR *Enterobacter cloacae* isolates obtained from clinical samples of children in Kermanshah, Iran,” *Journal of Clinical and Diagnostic Research*, vol. 12, no. 12, pp. 13–16, 2018.
- [30] F. Amini, S. Vaziri, H. A. Karimpour, S. Hasani, S. Mohamadi, and M. Azizi, “Antibiotic resistance pattern of urinary tract infection pathogens in children of Kermanshah in 2015,” *Razi Journal of Medical Sciences*, vol. 24, no. 155, pp. 20–27, 2017.

- [31] M. Karambin and M. Zarkesh, "Enterobacter, the most common pathogen of neonatal septicemia in Rasht, Iran," *Iranian Journal of Pediatrics*, vol. 21, no. 1, pp. 83–87, 2011.
- [32] T. Yaghubi, A. Pourkazemi, H. Farashbandi, and H. Balu, "Epidemiological study of nosocomial infections and antibiotic resistance patterns in Guilan," *Yafteh*, vol. 21, no. 1, pp. 52–62, 2019.
- [33] S. Rouhi, B. Mohammadi, R. Ramazan-zadeh, S. Mohammadi, and S. Zandi, "Prevalence of isolated bacterial and antibiotic resistant pattern of them in positive blood cultures isolated from patients admitted to different parts of Toohid Hospital of Sanandaj city (2013-2014)," *Navid No*, vol. 18, no. 60, pp. 34–41, 2015.
- [34] B. Nikkhoo, F. Lahurpur, A. Delpisheh, M. A. Rasouli, and A. Afkhamzadeh, "Neonatal blood stream infections in tertiary referral hospitals in Kurdistan, Iran," *Italian Journal of Pediatrics*, vol. 41, no. 1, pp. 43–44, 2015.
- [35] R. Ramazan-zadeh, M. Chitsaz, and N. Bahmani, "Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing bacteria in intensive care units of Sanandaj general hospitals (Kurdistan, Iran)," *Chemotherapy*, vol. 55, no. 4, pp. 287–292, 2009.
- [36] A. Afkhamzadeh, F. Lahoorpour, A. Delpisheh, and R. Janmardi, "Incidence of ventilator associated pneumonia (VAP) and bacterial resistance pattern in adult patients hospitalized at the intensive care unit of Besat Hospital in Sanandaj," *SJKU*, vol. 16, no. 1, pp. 20–26, 2011.
- [37] M. A. Jazayeri, "Frequency of the bacterial agents in urinary tract infection and their antibiotic susceptibility pattern in Semnan," *Journal of Semnan University Medical Science*, vol. 1, no. 4, pp. 1–16, 2000.
- [38] R. Khashei, F. Edalati Sarvestani, Y. Malekzadegan, and M. Motamedifar, "The first report of *Enterobacter gergoviae* carrying *bla*NDM-1 in Iran," *Iranian Journal of Basic Medical Sciences*, vol. 23, no. 9, pp. 1184–1190, 2020.
- [39] Y. Malekzadegan, M. Hadadi, H. S. Ebrahim-Saraie, H. Heidari, and M. Motamedifar, "Antimicrobial resistance pattern and frequency of multiple-drug resistant *Enterobacter* spp. at a tertiary care hospital in Southwest of Iran," *Journal of Krishna Institute of Medical Sciences University*, vol. 6, no. 2, pp. 33–39, 2017.
- [40] S. Nematollahi, A. Mosadegh, J. Mardaneh, and B. Poorabbas, "Identification of ESBL-producing and *bla*SHV gene harboring *Enterobacter* spp. isolated from bloodstream infections of hospitalized patients during 10 Years in south of Iran (Shiraz)," *Iranian South Medical Journal*, vol. 19, no. 4, pp. 536–548, 2016.
- [41] J. Mardaneh, M. Anvarinejad, A. Abbasian et al., "Emergence of multi-drug resistant ESBL producing strains among *Enterobacteriaceae* members isolated from patients blood samples in south of Iran," *Iranian South Medical Journal*, vol. 18, no. 5, pp. 970–981, 2015.
- [42] M. A. Rezaee and B. Abdinia, "Etiology and antimicrobial susceptibility pattern of pathogenic bacteria in children subjected to UTI: a referral hospital-based study in Northwest of Iran," *Medicine*, vol. 94, no. 39, 2015.
- [43] H. Hamishehkar, P. Shadmehr, A. Mahmoodpoor, S. O. Mashayekhi, and T. Entezari-Maleki, "Antimicrobial susceptibility patterns among bacteria isolated from intensive care units of the largest teaching hospital at the northwest of Iran," *Brazilian Journal of Pharmaceutical Sciences*, vol. 52, no. 3, pp. 403–412, 2016.
- [44] T. Azimi, S. Maham, F. Fallah, L. Azimi, and Z. Gholinejad, "Evaluating the antimicrobial resistance patterns among major bacterial pathogens isolated from clinical specimens taken from patients in Mofid Children's Hospital, Tehran, Iran: 2013–2018," *Infection and Drug Resistance*, vol. 12, pp. 2089–2102, 2019.
- [45] H. Akhavi-zadegan, H. Hosamirudsar, H. Pirroti, and S. Akbarpour, "Antibiotic resistance: a comparison between inpatient and outpatient uropathogens," *Eastern Mediterranean Health Journal*, vol. 27, no. 2, pp. 124–130, 2021.
- [46] M. Sohrabi fard, F. Noorbakhsh, and A. Elikaei, "Studying the prevalence of TetA and TetB in *Kelebsiella*, *Proteus* and *Enterobacter* isolated from urinary tract infection," *Medical Sciences*, vol. 26, no. 4, pp. 222–228, 2016.
- [47] R. Ghanavati, M. Emameini, D. Kalantar-Neyestanaki et al., "Clonal relation and antimicrobial resistance pattern of extended-spectrum  $\beta$ -lactamase-and AmpC  $\beta$ -lactamase-producing *Enterobacter* spp. isolated from different clinical samples in Tehran, Iran," *Journal of the Brazilian Society of Tropical Medicine*, vol. 51, no. 1, pp. 88–93, 2018.
- [48] K. Salimian Rizi, S. Najar Peerayeh, B. Bakhshi, and M. Rahbar, "Prevalence of integrons and antimicrobial resistance genes among clinical isolates of *Enterobacter* spp. from hospitals of Tehran," *International Journal of Enteric Pathogen*, vol. 3, no. 1, Article ID e22531, 2015.
- [49] S. Mahmoudi, M. Mahzari, M. Banar et al., "Antimicrobial resistance patterns of gram-negative bacteria isolated from bloodstream infections in an Iranian referral paediatric hospital: a 5.5-year study," *Journal of Global Antimicrobial Resistance*, vol. 11, pp. 17–22, 2017.
- [50] Z. Rajabi and M. M. Soltan Dallal, "Study on bacterial strains causing blood and urinary tract infections in the neonatal Intensive care unit and determination of their antibiotic resistance pattern," *Jundishapur Journal of Microbiology*, vol. 8, no. 8, Article ID e19654, 2015.
- [51] S. Afsharpaiman, F. Bairaghdar, M. Torkaman et al., "Bacterial pathogens and resistance patterns in children with community-acquired urinary tract infection: a cross sectional study," *Journal of Comprehensive Pediatrics*, vol. 3, no. 1, pp. 16–20, 2012.
- [52] M. Rahbar, L. Azimi, M. Mohammad-Zadeh et al., "The prevalence of nosocomial infections caused by *Enterobacter cloacae* and antibiotic resistant patterns in samples isolated from patients in two hospitals in Tehran," *Tehran University Medical Journal*, vol. 70, no. 3, pp. 183–187, 2012.
- [53] R. E. Ranjbar, A. M. Haghi, J. N. Joneydi, and M. Abedini, "The prevalence and antimicrobial susceptibility of bacterial uropathogens isolated from pediatric patients," *Iranian Journal of Public Health*, vol. 38, no. 2, pp. 134–138, 2009.
- [54] P. A. Taheri, B. Navabi, and E. Khatibi, "Frequency and susceptibility of bacteria caused urinary tract infection in neonates: eight-year study at neonatal division of Bahrami children's hospital, Tehran Iran," *Iranian Journal of Public Health*, vol. 42, no. 10, pp. 1126–1133, 2013.
- [55] A. M. Haghi, M. Abedini, N. K. Sadeghifard, S. Soroush, and K. M. Taheri, "Etiology and antibacterial resistance of bacterial urinary tract infections in children's medical center, Tehran, Iran," *Acta Medica Iranica*, vol. 45, no. 2, pp. 153–157, 2007.
- [56] M. Navidinia, M. Goudarzi, S. M. Rameshe et al., "Molecular characterization of resistance genes in MDR-ESKAPE pathogens," *Journal of Pure and Applied Microbiology*, vol. 11, no. 2, pp. 779–792, 2017.
- [57] S. Sadeghi Bojd, G. Soleimani, A. Teimouri, E. Zarifi, and S. Rashidi, "Evaluation of antibiotic sensitivity of urinary tract pathogens among children in Zahedan, south east of Iran,"

- International Journal of Pediatrics*, vol. 5, no. 10, pp. 5965–5974, 2017.
- [58] The Centers for Disease Control and Prevention, “Antibiotic resistance threats in the united states,” 2019, <https://www.cdc.gov/DrugResistance/Biggest-Threats.html>.
- [59] A. A. Elshamy and K. M. Aboshanab, “A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options,” *Future Science OA*, vol. 6, no. 3, Article ID FSO438, 2020.
- [60] H. Amin, A. Zafar, H. Ejaz, and N. U. A. Jameel, “Phenotypic characterization of ESBL producing *Enterobacter cloacae* among children,” *Pakistan Journal of Medical Sciences*, vol. 29, no. 1, pp. 144–147, 2013.
- [61] D. S. Teklu, A. A. Negeri, M. H. Legese, T. L. Bedada, H. K. Woldemariam, and K. D. Tullu, “Extended-spectrum beta-lactamase production and multi-drug resistance among *Enterobacteriaceae* isolated in Addis Ababa, Ethiopia,” *Antimicrobial Resistance and Infection Control*, vol. 8, no. 1, 2019.
- [62] C. C. Sheu, Y. T. Chang, S. Y. Lin, Y. H. Chen, and P. R. Hsueh, “Infections caused by carbapenem-resistant *Enterobacteriaceae*: an update on therapeutic options,” *Frontiers in Microbiology*, vol. 10, p. 80, 2019.
- [63] S. A. Bazghandi, M. Arzanlou, H. Peeridogaheh, H. Vaez, A. Sahebkar, and F. Khademi, “Prevalence of virulence genes and drug resistance profiles of *Pseudomonas aeruginosa* isolated from clinical specimens,” *Jundishapur Journal of Microbiology*, vol. 14, no. 8, Article ID e118452, 2021.
- [64] Z. Ghalehnoo, H. Vaez, A. Salehi-Abargouei, and F. Khademi, “Multidrug resistant *Pseudomonas aeruginosa* in Iran: a systematic review and metaanalysis,” *Journal of Global Infectious Diseases*, vol. 10, no. 4, pp. 212–217, 2018.